CoChat

GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy

Open access
Gong, Bing, Li, Couwen, Shi, Zhuang’e, Wang, FuPing, Dai, Ruanxian, Chen, Guobing, Su, Heng · 2025 · Frontiers in Pharmacology

The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have evolved into multi-organ potential therapeutics due to their pleiotropic effects beyond glycemic control. Mechanistically, GLP-1 signaling modulates immune and inflammatory pathways, regulates autophagy and pyroptosis, alleviates endoplasmic reticulum stress, and interacts with the gut microbiome. These pleiotropic effects provide a rationale for exploring their role in multiple organ systems. Clinical trials have demonstrated cardiovascular and renal protection, leading to additional approvals in high-risk populations. Early data also suggest potential benefits in liver disease, obstructive sleep apnea, chronic respiratory disorders, neurodegenerative and psychiatric conditions, reproductive dysfunction, obesity-associated cancers, and sepsis, although these remain investigational. Therefore, this review aims to synthesize the evidence on the mechanistic expansion of GLP-1RAs from metabolic regulators to systemic modulators of inflammation, autophagy, and organ protection, and explores their therapeutic repurposing across diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2025.1675552

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Milestones and publication trends of GLP-1/GLP-1 receptor agonists (1980–2025).
FIGURE 1 Milestones and publication trends of GLP-1/GLP-1 receptor agonists (1980–2025).CC BY · PubMed Central
FIGURE 2 Crosstalk between GLP-1 and the gut microbiome/metabolites.
FIGURE 2 Crosstalk between GLP-1 and the gut microbiome/metabolites.CC BY · PubMed Central
FIGURE 3 Association between GLP-lRAs use and cancer risk.
FIGURE 3 Association between GLP-lRAs use and cancer risk.CC BY · PubMed Central
FIGURE 4 Repurposing of GLP-1RAs.
FIGURE 4 Repurposing of GLP-1RAs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 36

Metadata

Authors
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H.
Affiliations
Kunming University of Science and Technology (CN)
Corresponding author
  • Chen, Guobing
  • Su, Heng
Venue
Frontiers in Pharmacology
Published
2025-09-11
Volume
16
Pages
1675552-1675552
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4414131365
Cited by
36
References
141
Citations by year
2026: 33 · 2025: 3
FWCI
4.87
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
GLP-1 receptor agonists, type 2 diabetes, obesity, pleiotropy, inflammation, autophagy, pyroptosis, endoplasmic reticulum stress, gut microbiota, cardioprotection, renal protection, liver disease, obstructive sleep apnea, neurodegenerative diseases, mental illness, reproductive disorders, obesity-related cancer, sepsis, drug repurposing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.